Kidswell Bio Corporation
4584.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.22 | -1.28 | 0.04 | -0.11 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -160.26 | 64.50 | 23.40 | 44.55 |
| Quality | ||||
| ROIC | 0.89% | 4.45% | 3.99% | 1.95% |
| Gross Margin | 25.43% | 34.71% | 29.79% | 41.84% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 59.41% | 58.05% | 48.40% | 97.63% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 5.09 | -6.97 | -7.66 | 6.14 |
| Interest Coverage | 3.73 | 19.33 | 16.40 | 12.88 |
| Efficiency | ||||
| Inventory Turnover | 0.88 | 1.14 | 0.97 | 0.76 |
| Cash Conversion Cycle | 187.15 | 107.59 | 136.16 | 124.57 |